Physicians' Academy for Cardiovascular Education

Potential role of PCSK9 inhibitors

3' education - Nov. 26, 2014 - VBWG Chicago - Michael J Koren



Dr Michael J Koren MD, Jacksonville, FL, USA, shares his rationale for targeting PCSK9, based on epidemiology and recent clinical developments and discusses implications for future lipid management

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: